Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.37 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL4504225 | 1.00 | ALDH1A1 (0.37) | ALDH1A1MAPTKMT2AMEN1HCAR2 | |
| Maleic Acid SCHEMBL27552413 | 1.00 | ALDH1A1 (0.37) | ALDH1A1MAPTKMT2AMEN1HCAR2 | |
| Oxalic Acid SCHEMBL8507926 | 0.88 | MAPT (0.39) | ALDH1A1MAPTKMT2AMEN1HTT | |
| Carbamic Acid SCHEMBL28658378 | 0.86 | MAPT (0.38) | ALDH1A1MAPTKMT2ALMNAGAA | |
| SCHEMBL34259 | 0.84 | GAA (0.48) | MAPTGAA | |
| Succinic Acid SCHEMBL5729591 | 0.83 | NR4A2 (0.43) | ALDH1A1MAPTKMT2AHDAC3HDAC4 | |
| Cadaverine Tartrate SCHEMBL3996512 | 0.82 | GAA (0.34) | MAPTLMNAKDM4EGAANPC1 | |
| Tartaric Acid SCHEMBL30548416 | 0.82 | GAA (0.34) | MAPTLMNAKDM4EGAANPC1 | |
| Cadaverine Tartrate SCHEMBL3996515 | 0.82 | GAA (0.34) | MAPTLMNAKDM4EGAANPC1 | |
| Trifluoroacetic Acid SCHEMBL5465747 | 0.82 | CES1 (0.39) | MAPTGAANPC1RAB9AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1885699-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | claimed |
| WO-2006125622-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | claimed |
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| CN-101184735-A | Crystalline form of benzazepinium maleate derivative | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | CN | disclosed |
| EP-1885699-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006125622-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | GLAXO GROUP LIMITED (GB) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163475-A1 | CRYSTALLINE FORM OF BENZAZEPINIUM MALEATE DERIVATIVE | CYP3A5, GABRA5, SLC6A13 | KMT2A 545/4885MEN1 2214/4885ALDH1A1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.